Related Experiment Videos
Current evidence does not support routine adjuvant radiotherapy for rectal cancer
1Department of Colorectal Surgery, St Vincents Hospital, Darlinghurst, New South Wales, Australia. alanpmeagher@yahoo.com
ANZ Journal of Surgery
|November 20, 2002
Summary
Routine adjuvant radiotherapy for rectal cancer does not improve survival in modern surgical practice. Evidence does not support its widespread use, as benefits are not consistently shown and quality of life impacts are unclear.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Widespread support exists for routine adjuvant radiotherapy in rectal cancer treatment.
- Recent evidence is reviewed, focusing on preoperative and postoperative radiotherapy.
- Key questions address survival and quality of life benefits.
Purpose of the Study:
- To review current evidence on adjuvant radiotherapy for rectal cancer.
- To evaluate survival benefits when surgery alone yields low local recurrence rates.
- To assess the impact of radiotherapy on patient quality of life.
Main Methods:
- Review of published literature, including recent studies and meta-analyses.
- Focus on preoperative radiotherapy (Stages I-III) and postoperative radiotherapy (Stages II-III).
- Analysis of studies addressing survival and quality of life outcomes.
Main Results:
- Survival benefit demonstrated in only one study and one meta-analysis.
- Modern surgical standards show no survival advantage with radiotherapy.
- Impact on quality of life is unknown; radiotherapy may have detrimental effects.
Conclusions:
- Current evidence does not support routine adjuvant radiotherapy for rectal cancer.
- Widespread advocacy for its use is not supported by recent trial data.
- Further investigation is needed regarding quality of life implications.